Xinglei Chai
Education
Ph.D., biostatistics, University of Pennsylvania; B.A., mathematics and economics, University of Arizona
Summary of Experience
Dr. Chai specializes in biostatistics and health economics and outcomes research (HEOR). She has extensive experience in developing and applying advanced statistical methods and machine learning tools to solve complex questions in the field of health outcomes research. Her expertise includes economic modeling, indirect treatment comparison, and real-world studies using clinical trial data, electronic medical records, medical chart reviews, and disease registries. Dr. Chai has also led submissions to health technology assessment agencies across the world, including those in the UK, France, Germany, Nordic countries, Canada, and Japan. Dr. Her work spans a variety of disease areas, such as oncology, blood disorders, autoimmune diseases, infectious diseases, women’s health, and chronic kidney diseases. Dr. Chai’s research has been published in many peer-reviewed journals and featured at various conferences.
-
Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma
Leukemia & Lymphoma, 2024
2024Dickinson M, Martinez-Lopez J, Jousseaume E, Yang H, Chai X, Xiang C, Wang T, Zhang J, Ramos R, Schuster SJ, Fowler N
-
Indirect Comparison of Tisagenlecleucel and Historical Treatments for Relapsed/Refractory Diffuse Large B-cell Lymphoma
Blood Advances, 2022
2022Maziarz RT, Zhang J, Yang H, Chai X, Yuan C, Schwarz E, Jakovac M, Martinez-Prieto M, Agarwal A, Degtyarev E, Tam C, Salles G
-
Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy
Journal of Managed Care & Specialty Pharmacy, 2022
2022Choi M, Song J, Bui CN, Ma E, Chai X, Yin L, Betts KA, Kapustyan T, Montez M, LeBlanc TM
-
Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective
PharmacoEconomics, 2022
2022Pratz KW, Chai X, Xie J, Yin L, Nie X, Montez M, Iantuono E, Downs L, Ma E
-
Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan
Transplantation and Cellular Therapy, 2021
2021Wakase S, Teshima T, Zhang J, Ma Q, Fujita T, Yang H, Chai X, Qi CZ, Liu Q, Wu EQ, Igarashi A
-
The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy
Advances in Therapy, 2021
2021Yu S, Smith A, Hass S, Wu E, Chai X, Zhou J, Ayyagari R, Liu JS, Robison D, Donelson SM, Tilles S
-
Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan
Transplantation and Cellular Therapy, 2021
2021Wakase S, Teshima T, Zhang J, Ma Q, Watanabe Y, Yang H, Qi CZ, Chai X, Xie Y, Wu EQ, Igarashi A
-
Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective
Journal of Managed Care & Specialty Pharmacy, 2020
2020 -
Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital’s perspective
Journal of Medical Economics, 2020
2020